Journey Medical Corporation (DERM)
NASDAQ:DERM
DERM Stock Chart & Stats
$5.17
-$0.02(-0.58%)
At close: 4:00 PM EST
$5.17
-$0.02(-0.58%)
Day’s Range― - ―
52-Week Range$4.31 - $9.56
Previous CloseN/A
Volume25.59K
Average Volume (3M)277.95K
Market Cap
$141.30M
Enterprise Value$102.68M
Total Cash (Recent Filing)$24.09M
Total Debt (Recent Filing)$119.00K
Price to Earnings (P/E)―
Beta0.52
Next Earnings
May 19, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding21,330,696
10 Day Avg. Volume248,845
30 Day Avg. Volume277,948
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)5.93
Price to Sales (P/S)3.05
P/FCF Ratio-15.18
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue1.66
Enterprise Value/Gross Profit2.80
Enterprise Value/Ebitda-29.52
Forecast
1Y Price Target
$13.50Price Target Upside161.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.25
Revenue Forecast (FY)$100.73M
Bulls Say, Bears Say
Bulls Say
Clinical Data And GuidelinesAnalyst points to robust clinical data and inclusion in treatment guidance for Emrosi as a factor that should bolster physician confidence and support payer discussions to improve access.
Prescriber AdoptionAnalyst cites strong prescription momentum and expanding prescriber adoption of Emrosi as evidence of durable demand that can drive sustained market share improvement.
Refill DynamicsAnalyst observes improving refill-to-new prescription ratios for Emrosi, indicating rising patient satisfaction and potential for sustained chronic use with recurring prescriptions.
Bears Say
Gross-to-Net DiscountsAnalyst warns elevated gross-to-net discounts are reducing reported revenue conversion for Emrosi, preventing prescription momentum from translating into financial results.
Revenue Recognition PressureAnalyst cautions that sustained high gross-to-net levels could suppress reported revenue and delay conversion of strong demand signals into visible financial performance, creating downside risk for the stock.
Journey Medical Corp News
DERM FAQ
What was Journey Medical Corporation’s price range in the past 12 months?
Journey Medical Corporation lowest stock price was $4.31 and its highest was $9.55 in the past 12 months.
What is Journey Medical Corporation’s market cap?
Journey Medical Corporation’s market cap is $141.30M.
When is Journey Medical Corporation’s upcoming earnings report date?
Journey Medical Corporation’s upcoming earnings report date is May 19, 2026 which is in 37 days.
How were Journey Medical Corporation’s earnings last quarter?
Journey Medical Corporation released its earnings results on Mar 25, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.052 by $0.012.
Is Journey Medical Corporation overvalued?
According to Wall Street analysts Journey Medical Corporation’s price is currently Undervalued.
Does Journey Medical Corporation pay dividends?
Journey Medical Corporation does not currently pay dividends.
What is Journey Medical Corporation’s EPS estimate?
Journey Medical Corporation’s EPS estimate is -0.08.
How many shares outstanding does Journey Medical Corporation have?
Journey Medical Corporation has 21,330,696 shares outstanding.
What happened to Journey Medical Corporation’s price movement after its last earnings report?
Journey Medical Corporation reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.052. Following the earnings report the stock price went down -30.015%.
Which hedge fund is a major shareholder of Journey Medical Corporation?
Currently, no hedge funds are holding shares in DERM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Journey Medical Corp Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.50 (161.12% Upside)
$13.50 (161.12% Upside)
Blogger Sentiment
Bullish
DERM Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 12.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.68%
12-Months-Change
Fundamentals
Return on Equity
-46.40%
Trailing 12-Months
Asset Growth
17.88%
Trailing 12-Months
Company Description
Journey Medical Corporation
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
DERM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive operational and commercial narrative driven by the successful launch of Emrosi—strong prescription growth, clinical validation (JAMA Dermatology publication and superiority vs Oracea), improved gross margins, a healthier balance sheet and the achievement of positive adjusted EBITDA. Key near-term risks remain: reliance on payer/formulary timing (yielding demand-to-revenue lag), variability in revenue per script driven by reimbursement mix and co-pay program usage, pressure on legacy products from generics, and planned incremental sales/SG&A spend. On balance, progress toward sustainable profitability and multiple tangible market-access and clinical milestones outweighed the challenges discussed.View all DERM earnings summariesDERM Stock 12 Month Forecast
Average Price Target
$13.50
▲(161.12% Upside)
Technical Analysis
Talphera
―
Assertio Therapeutics
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Alpha Teknova
―
Ownership Overview
14.69% Insiders
6.57% Mutual Funds
25.45% Other Institutional Investors
48.98% Public Companies and
Individual Investors